Levobupivacaina Molteni

Levobupivacaine, the active ingredient in Levobupivacaina Molteni, is a local anesthetic (amide) presented as a sterile solution for epidural use. It provides regional loss of sensation for surgical procedures, labor analgesia and postoperative pain control in adult patients. GNH USA supplies Levobupivacaina Molteni as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levobupivacaina is a local anesthetic used in epidural techniques to manage pain and facilitate surgery. - Epidural anesthesia for surgery: produces reversible loss of sensation in the operative region, allowing procedures without general anesthesia. - Labor and delivery analgesia: provides effective pain relief while preserving maternal consciousness and motor function. - Post‑operative pain management: extends analgesia after surgery, reducing the need for systemic opioids.

Adverse reactions may occur following epidural administration of levobupivacaine.

Common Side Effects: - Hypotension: decreased blood pressure due to sympathetic blockade. - Bradycardia: slowed heart rate, especially with high spinal spread. - Nausea and vomiting: gastrointestinal upset during onset. - Dizziness or light‑headedness: related to blood pressure changes. - Pruritus: itching at the injection site or generalized.

Serious or Rare Side Effects: - Cardiac arrest: severe arrhythmia or conduction block. - Seizures: central nervous system toxicity from high plasma levels. - Respiratory depression: inadequate ventilation, particularly with high blocks. - Allergic reaction: rash, urticaria, or anaphylaxis. - Spinal hematoma: bleeding in the epidural space causing neurologic compromise. - Persistent neurologic deficit: prolonged sensory or motor loss beyond expected duration.

When using levobupivacaina, clinicians should observe specific safety measures. - Dose adjustment in elderly: monitor hemodynamics and consider reduced volume. - Avoid in severe cardiac disease: risk of arrhythmias and conduction disturbances. - Use caution with concomitant CNS depressants: may enhance sedation or respiratory depression. - Assess coagulation status before epidural placement: to minimise risk of epidural hematoma. - Store at ambient temperature: keep in original container, protect from light and moisture.

Levobupivacaina may interact with other agents that affect cardiac or central nervous system function.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): increase risk of cardiotoxicity. - Beta‑blockers: potentiate bradycardia and hypotension. - High‑dose general anesthetics (e.g., propofol): additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Other local anesthetics (e.g., lidocaine): cumulative systemic toxicity. - Opioids: enhanced respiratory depression when combined epidurally. - Magnesium sulfate: may potentiate neuromuscular blockade and affect cardiac conduction.